A recent study from the from the Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, United States of America shows that “High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4.“ This study was published in the 8 Feb’13 issue of the Journal “Molecular Medicine” by Drs. Bauer PM, Bauer EM and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for pulmonary hypertension: MiRNA-181 suppresses pulmonary hypertension via down regulation of its target gene. This study suggests, for the first time, that MiRNA-181, by decreasing the expression of its target gene, may: (1) decrease Right ventricular systolic pressure, and (2) inhibit thickening of the pulmonary artery wall. Together, pharmacological formulations encompassing “MiRNA-181 or its activators“ may be used to treat patients suffering from pulmonary hypertension.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for pulmonary hypertension: MiRNA-181 suppresses pulmonary hypertension via down regulation of its target gene, 09/March/2015, 17.43, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How MiRNA-181 stifles pulmonary hypertension
Amount: $300*
